The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

Source: [CNBC](https://www.cnbc.com/2026/09/08/astrazeneca-copd-drug-tozorakimab-shows-positive-late-stage-trial-results.html)

Sponsored